3vm4
From Proteopedia
(Difference between revisions)
(New page: '''Unreleased structure''' The entry 3vm4 is ON HOLD Authors: Takashi, Fujishiro, Osami, Shoji, Shingo, Nagano, Hiroshi, Sugimoto, Yoshitsugu, Shiro, Yoshihito, Watanabe Description: C...) |
|||
(7 intermediate revisions not shown.) | |||
Line 1: | Line 1: | ||
- | '''Unreleased structure''' | ||
- | + | ==Cytochrome P450SP alpha (CYP152B1) in complex with (R)-ibuprophen== | |
+ | <StructureSection load='3vm4' size='340' side='right'caption='[[3vm4]], [[Resolution|resolution]] 1.94Å' scene=''> | ||
+ | == Structural highlights == | ||
+ | <table><tr><td colspan='2'>[[3vm4]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Sphingomonas_paucimobilis Sphingomonas paucimobilis]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3VM4 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3VM4 FirstGlance]. <br> | ||
+ | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.94Å</td></tr> | ||
+ | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=HEM:PROTOPORPHYRIN+IX+CONTAINING+FE'>HEM</scene>, <scene name='pdbligand=IZP:(2R)-2-[4-(2-METHYLPROPYL)PHENYL]PROPANOIC+ACID'>IZP</scene>, <scene name='pdbligand=MRD:(4R)-2-METHYLPENTANE-2,4-DIOL'>MRD</scene></td></tr> | ||
+ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3vm4 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3vm4 OCA], [https://pdbe.org/3vm4 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3vm4 RCSB], [https://www.ebi.ac.uk/pdbsum/3vm4 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3vm4 ProSAT]</span></td></tr> | ||
+ | </table> | ||
+ | == Function == | ||
+ | [https://www.uniprot.org/uniprot/O24782_SPHPI O24782_SPHPI] | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | The stereoselective epoxidation of styrene was catalyzed by H(2) O(2) -dependent cytochrome P450(SPalpha) in the presence of carboxylic acids as decoy molecules. The stereoselectivity of styrene oxide could be altered by the nature of the decoy molecules. In particular, the chirality at the alpha-positions of the decoy molecules induced a clear difference in the chirality of the product: (R)-ibuprofen enhanced the formation of (S)-styrene oxide, whereas (S)-ibuprofen preferentially afforded (R)-styrene oxide. The crystal structure of an (R)-ibuprofen-bound cytochrome P450(SPalpha) (resolution 1.9 A) revealed that the carboxylate group of (R)-ibuprofen served as an acid-base catalyst to initiate the epoxidation. A docking simulation of the binding of styrene in the active site of the (R)-ibuprofen-bound form suggested that the orientation of the vinyl group of styrene in the active site agreed with the formation of (S)-styrene oxide. | ||
- | + | Chiral-substrate-assisted stereoselective epoxidation catalyzed by H2O2-dependent cytochrome P450SPalpha.,Fujishiro T, Shoji O, Kawakami N, Watanabe T, Sugimoto H, Shiro Y, Watanabe Y Chem Asian J. 2012 Oct;7(10):2286-93. doi: 10.1002/asia.201200250. Epub 2012 Jun , 14. PMID:22700535<ref>PMID:22700535</ref> | |
- | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
+ | </div> | ||
+ | <div class="pdbe-citations 3vm4" style="background-color:#fffaf0;"></div> | ||
+ | == References == | ||
+ | <references/> | ||
+ | __TOC__ | ||
+ | </StructureSection> | ||
+ | [[Category: Large Structures]] | ||
+ | [[Category: Sphingomonas paucimobilis]] | ||
+ | [[Category: Fujishiro T]] | ||
+ | [[Category: Nagano S]] | ||
+ | [[Category: Shiro Y]] | ||
+ | [[Category: Shoji O]] | ||
+ | [[Category: Sugimoto H]] | ||
+ | [[Category: Watanabe Y]] |
Current revision
Cytochrome P450SP alpha (CYP152B1) in complex with (R)-ibuprophen
|